InventisBio (SH:688382) Xin Lang Cai Jing·2025-12-22 02:47Core Viewpoint - Yifang Bio has shown significant stock performance with a year-to-date increase of 126.24%, despite a recent decline over the past 60 days [1] Group 1: Stock Performance - As of December 22, Yifang Bio's stock price reached 30.09 CNY per share, with a trading volume of 1.25 billion CNY and a market capitalization of 17.403 billion CNY [1] - The stock has experienced a 3.76% increase over the last five trading days and a 13.89% increase over the last 20 trading days, while it has declined by 11.32% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on October 31, where it recorded a net buy of -39.2836 million CNY [1] Group 2: Financial Performance - For the period from January to September 2025, Yifang Bio reported a revenue of 30.8935 million CNY, reflecting a year-on-year growth of 61.27% [2] - The company recorded a net profit attributable to shareholders of -181 million CNY, which is a 40.59% increase compared to the previous year [2] Group 3: Shareholder Information - As of September 30, 2025, Yifang Bio had 12,400 shareholders, an increase of 26.17% from the previous period, with an average of 33,810 circulating shares per shareholder, down by 17.52% [2] - The largest circulating shareholder is Hong Kong Central Clearing Limited, holding 16.2161 million shares, an increase of 8.162 million shares from the previous period [2] - New entrants among the top ten circulating shareholders include Ping An Medical Health Mixed A and Yongying Medical Innovation Selected Mixed Initiated A [2]